ATAdriana Too

Adriana Too

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adriana Too has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Successful treatment of invasive Aspergillus rhinosinusitis and orbital aspergillosis with oral isavuconazole in a patient with contraindications to conventional first- and second-line therapy

    by Adriana Too, Leigh Sowerby, Lulu Bursztyn, Reza Rahimi

    Objectives: Acute invasive fungal rhinosinusitis represents a severe, life-threatening condition that necessitates prompt diagnosis and intervention. In this case report, we discuss the use of isavuconazole, a novel, broad-spectrum triazole antifungal, approved for use in Canada in 2019 (Government of Canada. Summary Basis of Decision – Cresemba – Health Canada. Summary Basis of Decision. 2019. Accessed 6 June 2024. https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00424#:~:text=Summary%20Basis%20of%20Decision%20(SBD)%20for%20Cresemba&text=Summary%20Basis%20of%20Decision%20(SBD)%20documents%20provide%20information%20related%20to,original%20authorization%20of%20a%20product) that can be considered an alternative to voriconazole. Methods: We present the case of a 78-year-old man with a unique case of invasive Aspergillus rhinosinusitis and orbital aspergillosis. He was admitted for urgent left maxillary antrostomy, left anterior and posterior ethmoidectomy, and left transorbital resection of lesion tissue with orbital decompression. His treatment course was complicated by a contraindication to voriconazole because of prolonged QTc interval and inability to tolerate IV amphotericin B. Key findings: The patient was treated with a 14-week course of isavuconazole as an alternative to voriconazole. At 3 months, there was no clinical evidence for infection, and the patient was sent for a computed tomography (CT) of the head and sinus to assess for evidence of active infection or bone destruction, which showed significant improvement in paranasal sinus inflammation and soft tissue infiltration. At his 6-month follow-up, his CT head showed regression in inflammatory change, with no deterioration in his sinusitis, and no further antifungal treatment was required. Conclusions: Given the novelty of isavuconazole, there has been limited experience with its use in the setting of rhinosinusitis and orbital invasive aspergillosis. This case highlights isavuconazole as a reasonable alternative to voriconazole and other triazoles in patients that are intolerant or have contraindications related to QTc prolongation.


  • Analgesic medication considerations for chronic pain management post-bariatric surgery

    by Sumani Vij, Adriana Too, Victor Tsang, Denise Kreutzwiser

    IntroductionBariatric surgery, an option for obesity management, can significantly alter gastrointestinal structure and processes. These changes can impact the pharmacokinetics (PK) of medications, which can translate to clinical differences in efficacy and safety. Chronic pain is prevalent in obesity and often persists post-bariatric surgery.Areas coveredThis narrative review examines the PubMed literature from 1990 to January 2024 for the impact of bariatric surgery on the management of chronic pain medications including non-opioid (acetaminophen, non-steroidal anti-inflammatory drugs, antidepressants, and cannabinoids) and opioid medications.Expert opinionAn individualized medication management approach is ideal for post-bariatric surgery patients, as PK parameters, type of surgery, time since surgery, and patient-specific factors make it difficult to support blanket recommendations. Close monitoring of efficacy and safety outcomes is essential in chronic pain management. While the PK of acetaminophen and opioids are impacted, the value of these medications in the setting of chronic pain is dwindling as more efficacy and safety data emerges. A life-long ban of NSAIDs due to marginal ulcer risk is not endorsed; rather, we advocate for shifting the focus to marginal ulcer prevention strategies, individualized benefit-risk analysis, and safety monitoring using surrogate markers.